Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$40.50 USD
+0.40 (1.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $40.53 +0.03 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
XENE 40.50 +0.40(1.00%)
Will XENE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XENE
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
Other News for XENE
Baron Health Care Fund Q1 2024 Shareholder Letter
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
Xenon Pharmaceuticals Spotlights XEN1101 Progress
Buy Rating Affirmed for Xenon: A Comprehensive Analysis of Market Position and Growth Prospects
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference